AcariaHealth, a leading national specialty pharmacy, is excited to announce its partnership with Leo Pharma to distribute ADBRY® (tralokinumab-ldrm). This innovative medication, approved by the U.S. Food and Drug Administration (FDA) in 2021, is designed to treat patients aged 12 and older with moderate-to-severe atopic dermatitis. ADBRY stands out as the first biologic injection specifically targeting and neutralizing IL-13, a protein involved in the inflammatory processes associated with atopic dermatitis.

Atopic dermatitis, often referred to as eczema, is a prevalent, non-contagious condition characterized by dry, itchy, and inflamed skin. It typically manifests in areas where the skin flexes, such as behind the knees and inside the elbows.

AcariaHealth is committed to enhancing patient lives through compassionate and comprehensive care. We ensure timely medication delivery, offer continuous support, and provide exceptional patient care throughout the treatment process. Both patients and healthcare providers can trust AcariaHealth for reliable service and unwavering support.

For detailed prescribing information, visit adbry.com, or find additional resources for healthcare professionals at adbryhcp.com.

Stay updated with the latest news from AcariaHealth by following us on LinkedIn for important announcements and industry insights.